Communicating anticancer treatment cessation and transition to palliative care: The need for a comprehensive and culturally relevant, person-centered approach

By  

Cancer, Vol. 121, Iss. 23, 2015-12 ,pp. : 4104-4107

Blackwell Publishing

Access to resources Recommend Favorite

Low molecular weight heparin (LMWH) is acceptable to patients with advanced cancer receiving palliative care

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial

By Lund Rasmussen Charlotte   Klee Olsen Marc   Thit Johnsen Anna   Aagaard Petersen Morten   Lindholm Helena   Andersen Line   Villadsen Birgit   Groenvold Mogens   Pedersen Lise  

Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. : 3727-3736

Blackwell Publishing

Access to resources Recommend Favorite

Measuring Treatment Preferences and Willingness to Pay for Docetaxel in Advanced Ovarian Cancer

By Dranitsaris G.  

PharmacoEconomics, Vol. 22, Iss. 6, 2004-01 ,pp. : 375-387

Adis International

Access to resources Recommend Favorite

Treatment of Locally Advanced Pancreatic Carcinoma in Sweden: A Health Economic Comparison of Palliative Treatment With Best Supportive Care Versus Palliative Treatment With Gemcitabine in Combination With Best Supportive Care

By Tennvall G.R.  

PharmacoEconomics, Vol. 15, Iss. 4, 1999-04 ,pp. : 377-384

Adis International

Access to resources Recommend Favorite